Better News Network

4 Reasons to Buy This Hybrid of a Growth and Income Stock

The pharmaceutical companys dividend is secure and the company's earnings should allow it to maintain solid growth in the future. The stock is a steal compared to its industry peers. The trifecta of a company with above-average growth prospects and above-average starting income at a below-average valuation is incredibly potent.

Thursday, November 17, 2022 at 11:25 am

Full Coverage